Feb 2, 2026 8:00 am EST Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Jan 27, 2026 7:00 am EST Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Dec 9, 2025 7:00 am EST Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
Nov 13, 2025 7:00 am EST Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
Nov 12, 2025 7:00 am EST Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update